This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
10 Apr 2019

Isotype-specific secondary antibodies for improved signal detection

Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Bio-Rad Laboratories has launched its isotype-specific secondary antibodies. This new range of recombinant monoclonal antibodies, directed against the three main mouse isotypes: IgG1, IgG2a, and IgG2b, offer improved signal detection and specificity in imaging, ELISA, flow cytometry, and western blotting.

Secondary antibodies are key components of antibody detection systems. The selection of an optimum secondary antibody can improve positive signals in addition to reducing false positive or negative staining. Recombinant monoclonal isotype-specific secondary antibodies detect individual isotypes, without species or isotype cross-reactivity, enabling multiple unlabeled mouse monoclonal antibodies of differing isotypes to be used simultaneously. This obviates the need to source secondary antibodies from other species. The isotype-specific antibodies offer an alternative to cross-adsorbed secondary antibodies when absolute specificity is required, for instance, during multiplexing or to prevent nonspecific background staining.

Bio-Rad’s recombinant monoclonal antibodies are generated using the Human Combinatorial Antibody Library (HuCAL) and CysDisplay, a proprietary method of phage display with guided selection methods to obtain highly targeted reagents. The recombinant production method also ensures consistent and secure supply.

“Recombinant human monoclonal antibodies are selected against epitopes unique to the isotype and offer significant advantages over traditional secondary antibodies,” said Tracey Long, Bio-Rad Marketing Manager, Life Science Group. “Bio-Rad’s recombinant monoclonal isotype-specific antibodies are easy to use and can be substituted for any secondary in the protocol without the need for extra steps,” she added.

Related categories
Antibodies Innovative APIs

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.